Cofrogliptin - Haisco Pharmaceutical Group
Alternative Names: HSK 7653Latest Information Update: 06 Aug 2024
At a glance
- Originator Haisco Pharmaceutical Group
- Class Amines; Antihyperglycaemics; Fluorinated hydrocarbons; Fluorobenzenes; Pyrans; Pyrazoles; Pyrroles; Small molecules; Sulfones
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Type 2 diabetes mellitus
- Discontinued Glucose intolerance
Most Recent Events
- 05 Aug 2024 Discontinued - Phase-II for Glucose intolerance in China (PO) prior to August 2024 (Haisco Pharmaceutical Group)
- 25 Jun 2024 Launched for Type 2 diabetes mellitus in China (PO) - First global launch
- 24 Jun 2024 Preregistration for Type 2 diabetes mellitus in China (PO) prior to June 2024